Cover Image
市場調查報告書

細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13):開發中產品分析

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 358696
出版日期 內容資訊 英文 109 Pages
訂單完成後即時交付
價格
Back to Top
細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13):開發中產品分析 Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 109 Pages
簡介

本報告提供全球各國治療細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要的疾病及藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 細胞性腫瘤抗體P53 (腫瘤抑制劑P53/抗體NY-CO-13)的概要
  • 治療藥的開發
    • 臨床實驗中的產品:臨床實驗的各階段
    • 臨床實驗中的產品:各治療領域
    • 臨床實驗中的產品:不同症狀
  • 開發中產品的概要
    • 臨床實驗後期階段的產品
    • 臨床實驗初期階段的產品
  • 各企業開發中的產品
  • 各大學/研究機關開發中的產品
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥途徑
    • 各分子類型
  • 細胞性腫瘤抗體P53 (腫瘤抑制劑P53/抗體NY-CO-13) 治療藥的開發企業
    • Advaxis, Inc.
    • American Gene Technologies International Inc.
    • Aprea AB
    • Cellceutix Corporation
    • Critical Outcome Technologies Inc.
    • Eleos Inc.
    • ORCA Therapeutics B.V.
    • OSE Pharma SA
    • PCI Biotech Holding ASA
    • Quark Pharmaceuticals, Inc.
    • Stemline Therapeutics, Inc.
    • Shenzen SiBiono GeneTech Co., Ltd.
    • SK Biopharmaceuticals Co., Ltd.
    • Tara Immuno-Oncology Therapeutics LLC
    • Z53 Therapeutics, LLC
  • 藥物簡介
    • Adxs-LmddA159
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • AG-1101
    • APR-017
    • APR-246
    • ATRN-502
    • cenersen sodium
    • contusugene ladenovec
    • COTI-2
    • D-12PGJ3
    • Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma
    • Gene Therapy to Activate p53 for Oncology
    • KM-3174
    • MHY-449
    • MJ-05
    • MX-225
    • N-2
    • Oncolytic Viruses to Activate p53 for Oncology
    • OSE-2101
    • p28
    • QPAL-1
    • QPI-1002
    • Recombinant Protein to Activate p53 for Oncology
    • SGT-53
    • SL-801
    • Small Molecule to Activate p53 for Cancer
    • Small Molecules to Activate p53 for Cancer and Viral Infections
    • Small Molecules to Activate p53 for Melanoma
    • Vaccine to Target Cellular Tumor Antigen p53 for Oncology
    • ZMC-1
  • 開發暫停的計劃
  • 開發中止的計劃
  • 值得注意的最新趨勢·新聞稿 (全10件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1075TDB

Summary:

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation. Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity.

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 26 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 5, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Respiratory and Toxicology which include indications Breast Cancer, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Colorectal Cancer, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Bladder Cancer, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hepatocellular Carcinoma, Melanoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Skin Cancer, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bacterial Infections, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Brain Tumor, Chemotherapy Effects, Esophageal Cancer, Glioma, Hematological Tumor, Hepatic - Colorectal Metastasis, Kidney Transplant Rejection, Leukemias, Liposarcoma, Malignant Mesothelioma, Malignant Pleural Effusion, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma, Solid Tumor, Thymoma (Thymic Epithelial Tumor), Transitional Cell Cancer (Urothelial Cell Cancer) and Viral Infections.

The latest report Cellular Tumor Antigen p53 - Pipeline Review, H2 2017, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Overview
    • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development
    • Aprea AB
    • CanBas Co Ltd
    • Critical Outcome Technologies Inc
    • Innovation Pharmaceuticals Inc
    • ORCA Therapeutics BV
    • OSE Immunotherapeutics
    • Quark Pharmaceuticals Inc
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles
    • APR-246 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATRN-502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • contusugene ladenovec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COTI-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-12PGJ3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kevetrin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MHY-449 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MJ-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MX-225 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oncolytic Viruses to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSE-2101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • p28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPAL-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPI-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGT-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SL-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate p53 for Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate p53 for Oncology and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate p53 for Skin Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZMC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Products
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 16, 2017: Karolinska Developments portfolio company Aprea announces first patient enrolled in clinical phase 1b/2 study with APR-246 for the treatment of esophageal cancer
      • Oct 11, 2017: Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma
      • Sep 14, 2017: Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial
      • Sep 11, 2017: Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017
      • Aug 30, 2017: Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress
      • Aug 14, 2017: Critical Outcome Technologies Completes Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
      • Aug 02, 2017: Karolinska Development company Aprea Therapeutics announces First Patient Enrolled in Phase Ib/II Clinical Study
      • Jul 27, 2017: Quark Pharmaceuticals Reports Positive Results from a Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury (AKI) in Subjects at High Risk of AKI Following Cardiac Surgery
      • Jun 23, 2017: OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi in Advanced Lung Cancer
      • May 30, 2017: Cellceutix Anti-Cancer Drug Candidates p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting
      • May 23, 2017: Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Myelodysplastic Syndrome
      • Apr 03, 2017: Cellceutix AACR Poster Presents Data Supporting Kevetrin Modulation of p53 in Multiple Human Ovarian Cancer Cell-lines and Corresponding Xenograft Tumors
      • Mar 03, 2017: Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent
      • Feb 21, 2017: Stemline Therapeutics Provides Update on SL-801
      • Feb 10, 2017: Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p53 Drug Candidate Kevetrin in the Treatment of Platinum-Resistant/Refractory Ovarian Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Aprea AB, H2 2017
  • Pipeline by CanBas Co Ltd, H2 2017
  • Pipeline by Critical Outcome Technologies Inc, H2 2017
  • Pipeline by Innovation Pharmaceuticals Inc, H2 2017
  • Pipeline by ORCA Therapeutics BV, H2 2017
  • Pipeline by OSE Immunotherapeutics, H2 2017
  • Pipeline by Quark Pharmaceuticals Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Dormant Products, H2 2017 (Contd..3), H2 2017
  • Dormant Products, H2 2017 (Contd..4), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top